Charleston Laboratories, Inc. and co-development and commercialization partner, Daiichi Sankyo, Inc., have completed a pharmacokinetics study on CL-108, Charleston’s lead product in development for moderate to severe pain and the prevention of opioid-induced nausea and vomiting.   CL-108 is a tablet containing 7.5 mg of hydrocodone and 325 mg of acetaminophen with 12.5 mg of fast-absorbed promethazine.    “This study demonstrated that CL-108 provides comparable bioavailability of hyd...